Literature DB >> 21309750

The Cdc42-associated kinase ACK1 is not autoinhibited but requires Src for activation.

Wing Chan1, Soon-Tuck Sit, Ed Manser.   

Abstract

The non-RTK (receptor tyrosine kinase) ACK1 [activated Cdc42 (cell division cycle 42)-associated kinase 1] binds a number of RTKs and is associated with their endocytosis and turnover. Its mode of activation is not well established, but models have suggested that this is an autoinhibited kinase. Point mutations in its SH3 (Src homology 3)- or EGF (epidermal growth factor)-binding domains have been reported to activate ACK1, but we find neither of the corresponding W424K or F820A mutations do so. Indeed, deletion of the various ACK1 domains C-terminal to the catalytic domain are not associated with increased activity. A previous report identified only one major tyrosine phosphorylated protein of 60 kDa co-purified with ACK1. In a screen for new SH3 partners for ACK1 we found multiple Src family kinases; of these c-Src itself binds best. The SH2 and SH3 domains of Src interact with ACK1 Tyr518 and residues 623-652 respectively. Src targets the ACK1 activation loop Tyr284, a poor autophosphorylation site. We propose that ACK1 fails to undergo significant autophosphorylation on Tyr284 in vivo because it is basophilic (whereas Src is acidophilic). Subsequent ACK1 activation downstream of receptors such as EGFR (EGF receptor) (and Src) promotes turnover of ACK1 in vivo, which is blocked by Src inhibitors, and is compromised in the Src-deficient SYF cell line. The results of the present study can explain why ACK1 is responsive to so many external stimuli including RTKs and integrin ligation, since Src kinases are commonly recruited by multiple receptor systems.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21309750     DOI: 10.1042/BJ20102156

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  10 in total

1.  Phosphatase of regenerating liver 3 (PRL3) provokes a tyrosine phosphoproteome to drive prometastatic signal transduction.

Authors:  Chad D Walls; Anton Iliuk; Yunpeng Bai; Mu Wang; W Andy Tao; Zhong-Yin Zhang
Journal:  Mol Cell Proteomics       Date:  2013-09-12       Impact factor: 5.911

2.  Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.

Authors:  Chelsea Jenkins; Samuel B Luty; Julia E Maxson; Christopher A Eide; Melissa L Abel; Corinne Togiai; Eneida R Nemecek; Daniel Bottomly; Shannon K McWeeney; Beth Wilmot; Marc Loriaux; Bill H Chang; Jeffrey W Tyner
Journal:  Sci Signal       Date:  2018-07-17       Impact factor: 8.192

3.  Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis.

Authors:  Julia E Maxson; Melissa L Abel; Jinhua Wang; Xianming Deng; Sina Reckel; Samuel B Luty; Huahang Sun; Julie Gorenstein; Seamus B Hughes; Daniel Bottomly; Beth Wilmot; Shannon K McWeeney; Jerald Radich; Oliver Hantschel; Richard E Middleton; Nathanael S Gray; Brian J Druker; Jeffrey W Tyner
Journal:  Cancer Res       Date:  2015-12-17       Impact factor: 12.701

4.  Proximity-Dependent Biotinylation to Elucidate the Interactome of TNK2 Nonreceptor Tyrosine Kinase.

Authors:  Raiha Tahir; Anil K Madugundu; Savita Udainiya; Jevon A Cutler; Santosh Renuse; Li Wang; Nicole A Pearson; Christopher J Mitchell; Nupam Mahajan; Akhilesh Pandey; Xinyan Wu
Journal:  J Proteome Res       Date:  2021-08-24       Impact factor: 4.466

5.  Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.

Authors:  Meghan L Rudd; Hassan Mohamed; Jessica C Price; Andrea J O'Hara; Matthieu Le Gallo; Mary Ellen Urick; Pedro Cruz; Suiyuan Zhang; Nancy F Hansen; Andrew K Godwin; Dennis C Sgroi; Tyra G Wolfsberg; James C Mullikin; Maria J Merino; Daphne W Bell
Journal:  BMC Cancer       Date:  2014-11-26       Impact factor: 4.430

6.  An Evolutionarily Conserved Pathway Essential for Orsay Virus Infection of Caenorhabditis elegans.

Authors:  Hongbing Jiang; Kevin Chen; Luis E Sandoval; Christian Leung; David Wang
Journal:  mBio       Date:  2017-09-05       Impact factor: 7.867

7.  Hepatocyte Growth Factor-Dependent Antiviral Activity of Activated cdc42-Associated Kinase 1 Against Hepatitis B Virus.

Authors:  Hye Won Lee; Yongwook Choi; Ah Ram Lee; Cheol-Hee Yoon; Kyun-Hwan Kim; Byeong-Sun Choi; Yong Kwang Park
Journal:  Front Microbiol       Date:  2021-12-23       Impact factor: 5.640

8.  Cortactin is a substrate of activated Cdc42-associated kinase 1 (ACK1) during ligand-induced epidermal growth factor receptor downregulation.

Authors:  Laura C Kelley; Scott A Weed
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

9.  Ack1: activation and regulation by allostery.

Authors:  Ketan S Gajiwala; Karen Maegley; RoseAnn Ferre; You-Ai He; Xiu Yu
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

10.  Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.

Authors:  Catherine Wilson; Katrina Nicholes; Daisy Bustos; Eva Lin; Qinghua Song; Jean-Philippe Stephan; Donald S Kirkpatrick; Jeff Settleman
Journal:  Oncotarget       Date:  2014-09-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.